NSE · HALEOSLABS
Haleos Labs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹63 Cr with net profit ₹2 Cr — a 3.52% net margin, versus 6.7% the period before.
Shareholding
As of 2026-06-30
- Promoter72.11%
- Public27.58%
- DII0.31%
6,859 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.66× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #56 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,74,684 Cr | 38.19 | 5.68 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,278 Cr | 214.92 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,12,139 Cr | 20.64 | 4.14 | 18.59% | 18.86% |
| Lupin Limited | ₹1,12,118 Cr | 70.4 | 4.99 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,181 Cr | 193.1 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,251 Cr | 344.6 | 18.15 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,311 Cr | 430.91 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,539 Cr | 100.46 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,966 Cr | 546.39 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,746 Cr | 286.6 | 4.9 | 16.66% | 15.65% |
| Haleos Labs Limited(this company) | ₹460 Cr | 1055.49 | 2.15 | 0.08% | 0.05% |
AI analysis
AI-generated · google/gemini-2.5-flashHaleos Labs Limited operates in the Pharmaceuticals sector with a market capitalization of Rs 475 Cr. The company reported a profit margin of 5.19% and a revenue growth rate of 12.67%. The TTM EPS is Rs 57.26.
Positives
- +The debt-to-equity ratio is 0.5, indicating a moderate level of debt relative to equity.
- +The promoter holding is substantial at 72.1062% as of June 30, 2026.
- +No promoter shares are reported as pledged, with promoter pledge at 0% as of June 30, 2026.
Negatives
- −The PE ratio is high at 1090.97.
- −The annual net profit declined from Rs 2.68 Cr in Mar 2025 to Rs 2.23 Cr in Mar 2026.
- −The quarterly net profit significantly dropped from Rs 6.62 Cr in Dec 2025 to Rs 0.44 Cr in Mar 2026.
- −The reported profit margin is relatively low at 5.19%.
- −No quarterly results have been disclosed after March 2026.
Financial Performance
Haleos Labs Limited reported an annual revenue of Rs 85.43 Cr for Mar 2025, which then decreased to Rs 63.38 Cr in Mar 2026. Quarterly revenue for Dec 2025 was Rs 94.78 Cr, and net profit was Rs 6.62 Cr. However, revenue for Mar 2026 declined to Rs 75.14 Cr with a net profit of Rs 0.44 Cr.
Profitability & Returns
The company's Return on Equity (ROE) stands at 8.11%, and Return on Capital Employed (ROCE) is 9.76%. The profit margin is 5.19%. Quarterly net profit for Haleos Labs Limited was Rs 6.62 Cr in Dec 2025, falling to Rs 0.44 Cr in Mar 2026.
Balance Sheet
Haleos Labs Limited has a book value of Rs 706.33. The company's debt-to-equity ratio is 0.5. No specific annual revenue figures are available for the entire fiscal year to determine overall financial scale.
Ownership & Pledges
There are no promoter pledges reported for June 30, 2026. The number of shareholders as of June 30, 2026, is 6,859.
Regulatory & Surveillance
No information regarding regulatory or surveillance actions on Haleos Labs Limited has been provided in the available data.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.